Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial

O. Metzger Filho, F. Cardoso, C. Poncet, C. Desmedt, S. Linn, J. Wesseling, F. Hilbers, S. Delaloge, J. Y. Pierga, E. Brain, S. Vrijaldenhoven, P. A. Neijenhuis, E. J.Th Rutgers, M. Piccart, L. J. van ’t Veer, G. Viale

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    Résumé

    Background: Evaluation of the prognostic performance and clinical utility of the MammaPrint 70-gene signature in early-stage invasive lobular carcinoma (ILC) for whom such analyses in a randomized trial is awaited. Patients and methods: Exploratory subgroup analysis of MINDACT trial patients with centrally assessed histology (n = 5929) with invasive breast cancer of no-special-type (NST), or pure ILC. In the trial patients were categorized based on the 70-gene signature for genomic risk and modified Adjuvant!Online for clinical risk. Survival outcomes at 8.7 years median follow-up by 70-gene signature were compared between NST and ILC for Distant Metastasis-Free Survival (DMFS), Disease-Free Survival (DFS) and Overall Survival (OS). Results: 5313 patients were ILC (n = 487) or NST (n = 4826). ILC was further classified into classic ILC (n = 255) or ILC variants (n = 232). The 70-gene signature classified 16.2 % of ILC and 39.1 % of NST as genomic high-risk (gH). Survival outcomes for ILC vs. NST revealed similar estimates according to genomic risk overall and across subsets. The 70-gene signature classified 10.2 % of classic ILC and 22.8 % of ILC variants as gH. 5-yr DFS estimates for ILC variants 88.4 % (95 %CI: 83.1–92.1) was inferior to classic ILC 93.0 % (95 %CI: 88.7–95.7). Conclusions: Sixteen percent of ILC were classified high genomic risk by the 70-gene signature, with unfavorable survival outcomes. Survival estimates were similar for patients with ILC and NST classified as either low- or high-genomic risk, suggesting that the 70-gene signature also has prognostic value in ILC and may be a clinically useful tool for adjuvant treatment decision-making in ILC.

    langue originaleAnglais
    Numéro d'article115222
    journalEuropean Journal of Cancer
    Volume217
    Les DOIs
    étatPublié - 25 févr. 2025

    Contient cette citation